Skip to content

US · BOLD · BIOTECHNOLOGY

Boundless Bio, Inc. (BOLD) intrinsic value and stock valuation

$2.32as of 2026-11-21 · Mkt cap 62.93M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Boundless Bio, Inc. DCF and intrinsic value

InvestorsCraft values BOLD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BOLD’s statements →

Boundless Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 boundlessbio.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$0.00
20162025
Net income
-$-58.2M
20162025
Free cash flow
-$-47.21M
20162025
Total equity
$98.7M-25.9% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-63.55M-$-73.27M-$-54.8M-$-46.47M-$-25.3M
Net income-$-58.2M-$-65.36M-$-49.43M-$-45.9M-$-25.21M
EPSd-$-2.6M-$-3.85M-$-2.22M-$-2.06M-$-1.13M
Operating cash flow-$-46.66M-$-60.84M-$-46.85M-$-39.6M-$-23.25M
Capital expenditure-$-550K-$-2.54M-$-630K-$-1.07M-$-2.03M
Free cash flow-$-47.21M-$-63.38M-$-47.49M-$-40.66M-$-25.28M
Total assets$157.1M$206.4M$129.9M$76.8M$113.7M
Total debt$49M$47.6M$2.19M$5.18M$380K
Net debt$31.2M$21.1M-$-21.51M-$-5.77M-$-33.91M
Total equity$98.7M$150.6M-$-127.08M-$-81.7M-$-38.19M
Cash and short-term investments$107.6M$152.1M$120.8M$66.7M$73M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$1.25M$1.09M$0.00$0.00$0.00
Gross profit-$-1.25M-$-1.09M$0.00$0.00$0.00
Research and development expenses$44.8M$55.3M$42.6M$37.2M$19.3M
Selling, general and administrative expenses$18.7M$18M$12.2M$9.31M$6.02M
Other expenses-$-1.25M-$-1.09M$0.00$0.00$0.00
Operating expenses$62.3M$72.2M$54.8M$46.5M$25.3M
Cost and expenses$63.6M$73.3M$54.8M$46.5M$25.3M
Interest income$5.36M$7.89M$5.28M$670K$100K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.25M$1.09M$960K$940K$680K
Ebitda-$-56.95M-$-64.28M-$-48.48M-$-44.96M-$-24.53M
Operating income-$-63.55M-$-73.27M-$-54.8M-$-46.47M-$-25.3M
Total other income/expenses, net$5.36M$7.9M$5.36M$570K$90K
Income before tax-$-58.2M-$-65.36M-$-49.43M-$-45.9M-$-25.21M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-58.2M-$-65.36M-$-49.43M-$-45.9M-$-25.21M
Weighted average shares outstanding$22.4M$17M$22.2M$22.2M$22.2M
Weighted average diluted shares outstanding$22.4M$17M$22.2M$22.2M$22.2M
Balance sheet
20252024202320222021
Cash and short-term investments$107.6M$152.1M$120.8M$66.7M$73M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$109.6M$154.4M$124.2M$68M$74.6M
Property, plant and equipment, net$46.9M$51.4M$4.58M$7.73M$3.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$560K$0.00$35M
Total non-current assets$47.5M$52M$5.69M$8.79M$39.2M
Total assets$157.1M$206.4M$129.9M$76.8M$113.7M
Accounts payable$1.49M$1.27M$2.22M$1.4M$1.07M
Short-term debt$3.17M$0.00$2.19M$2.34M$380K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$12.5M$8.13M$9.36M$7.73M$3.87M
Long-term debt$45.9M$47.6M$0.00$2.85M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$45.9M$47.6M$247.6M$150.8M$148M
Capital lease obligations$49M$47.6M$2.19M$5.18M$380K
Total liabilities$58.4M$55.8M$257M$158.5M$151.9M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-259.67M-$-201.47M-$-136.11M-$-86.67M-$-40.77M
Accumulated other comprehensive income (loss)$60K$120K$40K-$-400K-$-170K
Total equity$98.7M$150.6M-$-127.08M-$-81.7M-$-38.19M
Total investments$89.7M$125.5M$97.6M$55.8M$73.7M
Total debt$49M$47.6M$2.19M$5.18M$380K
Net debt$31.2M$21.1M-$-21.51M-$-5.77M-$-33.91M
Cash flow statement
20252024202320222021
Net income-$-58.2M-$-65.36M-$-49.43M-$-45.9M-$-25.21M
Depreciation and amortization$1.25M$1.09M$960K$940K$680K
Stock-based compensation$6.12M$7.52M$3.34M$2.29M$1.16M
Change in working capital$3.46M-$-1.68M-$-800K$870K-$-840K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.63M$780K$0.00$1.91M$0.00
Net cash provided by operating activities-$-46.66M-$-60.84M-$-46.85M-$-39.6M-$-23.25M
Investments in property, plant and equipment-$-550K-$-2.54M-$-630K-$-1.07M-$-2.03M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$37.8M-$-26.1M-$-38.26M$16.1M-$-59.28M
Common stock issued$140K$93M$0.00$130K$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$140K$89.8M$97.9M$130K$105.5M
Net change in cash-$-8.72M$2.88M$12.8M-$-23.34M$23M
Cash at end of period$18.4M$27.2M$24.3M$11M$34.8M
Operating cash flow-$-46.66M-$-60.84M-$-46.85M-$-39.6M-$-23.25M
Capital expenditure-$-550K-$-2.54M-$-630K-$-1.07M-$-2.03M
Free cash flow-$-47.21M-$-63.38M-$-47.49M-$-40.66M-$-25.28M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Boundless Bio, Inc.

        Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

        CEO
        Zachary Hornby
        Employees
        28
        Beta
        0.40

        Explore

        Frequently asked questions

        What is the intrinsic value of Boundless Bio, Inc. (BOLD)?

        InvestorsCraft does not currently publish an intrinsic value for BOLD. How the IC value is calculated.

        Is BOLD undervalued?

        InvestorsCraft does not publish an undervaluation signal for BOLD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.